Compare DOCS & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOCS | EWTX |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.7B |
| IPO Year | 2021 | 2021 |
| Metric | DOCS | EWTX |
|---|---|---|
| Price | $20.42 | $40.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 6 |
| Target Price | ★ $45.50 | $39.00 |
| AVG Volume (30 Days) | ★ 2.9M | 1.1M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | ★ $644,863,000.00 | N/A |
| Revenue This Year | $15.08 | N/A |
| Revenue Next Year | $8.83 | N/A |
| P/E Ratio | $20.87 | ★ N/A |
| Revenue Growth | ★ 13.05 | N/A |
| 52 Week Low | $17.15 | $12.31 |
| 52 Week High | $76.51 | $48.40 |
| Indicator | DOCS | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.34 | 52.30 |
| Support Level | $20.55 | $37.81 |
| Resistance Level | $21.07 | $43.93 |
| Average True Range (ATR) | 0.85 | 2.69 |
| MACD | -0.17 | -0.52 |
| Stochastic Oscillator | 15.43 | 29.06 |
Doximity Inc provides an online platform, which enables physicians and other healthcare professionals to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. The Company's customers include pharmaceutical companies and health systems that connect with healthcare professionals through the Company's digital Marketing, Hiring, and Workflow Solutions. Marketing Solutions provide customers with the ability to share tailored content on the network. Hiring Solutions enable customers to identify, connect with, and hire from the network of both active and passive potential medical professional candidates.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.